Short Bowel Syndrome Diagnostics and Treatment Market by Test types, Drug Classes, Trends, and Forecast to 2021, Upcoming Report by iHealthcareAnalyst, Inc..
Browse Short Bowel Syndrome Diagnostics and Treatment Market by Test Type (Complete Blood Test, Fecal Fat Test, Imaging Tests - X-Ray, Ct Scan, Others), and Drug Class (GLP-2, Growth Hormone, L-Glutamine, Others) and Forecast 2017-2021 at https://www.ihealthcareanalyst.com/report/short-bowel-syndrome-diagnostics-treatment-market/
The global short bowel syndrome diagnostics and treatment market segmentation is based on test type (complete blood test, fecal fat test, imaging tests such as X-ray, CT scan, others) and drug class (GLP-2, growth hormones, and L-glutamine, others).
The global short bowel syndrome diagnostics and treatment market report provides market size (Revenue USD Million 2014 to 2021), market share and forecasts growth trends (CAGR%, 2017 to 2021). The global short bowel syndrome diagnostics and treatment market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global short bowel syndrome diagnostics and treatment market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and also tracks the major competitors operating in the market and provides analysis of the company overview, financial snapshot, key products, technologies and services offered, market share analysis and recent trends in the global market.
Major players operating in the global short bowel syndrome diagnostics and treatment market and included in this report are Ardelyx, Inc., Emmaus Life Sciences, Inc., GLyPharma Therapeutic, Inc., Merck KGaA, Naia Pharmaceuticals, Inc., Nutrinia Ltd., OxThera, Sancilio and Company, Inc., Shire plc, and Zealand Pharma A/S.
1. Test Type
1.1. Complete Blood Test
1.2. Fecal Fat Test
1.3. Imaging Tests
1.3.2. CT Scan
2. Drug Class
2.2. Growth Hormones
3.1. North America (U.S., Canada)
3.2. Latin America (Brazil, Mexico, Rest of LA)
3.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
3.4. Asia Pacific (Japan, China, India, Rest of APAC)
3.5. Rest of the World
4. Company Profiles
4.1. Ardelyx, Inc.
4.2. Emmaus Life Sciences, Inc.
4.3. GLyPharma Therapeutic, Inc.
4.4. Merck KGaA
4.5. Naia Pharmaceuticals, Inc.
4.6. Nutrinia Ltd.
4.8. Sancilio and Company, Inc.
4.9. Shire plc
4.10. Zealand Pharma A/S
To request Table of Contents and Sample Pages of this report visit:
iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.
In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client's specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
Contact via Email
Read the full story here: http://www.pr.com/press-release/714806
|Printer friendly Cite/link Email Feedback|
|Publication:||PR.com (Press Releases)|
|Date:||May 4, 2017|
|Previous Article:||Healthcare Bio-MEMS Market by Products, Applications, Growth Trends and Forecast to 2021, Upcoming Report by iHealthcareAnalyst, Inc..|
|Next Article:||Robert Miller Acknowledges Future Electronics Team on New Franchise Agreement with Gemalto.|